Collaboration between Qiagen and Incyte to develop a novel diagnostic panel, leveraging FDA approvals for market access in the US.
2 reports, 0 independent
Updated Jul 1
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Collaboration between Qiagen and Incyte to develop a novel diagnostic panel, leveraging FDA approvals for market access in the US.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- Qiagen received FDA clearance for its diagnostic product, QIAstat-Dx Rise, expanding access in the U.S. on September 3, 2025.
- FDA review extended for ruxolitinib cream, while Incyte benefits from potential Trump-era tariffs, leading to analyst upgrades and recommendations.
- A product was launched in the U.S. market following FDA involvement.
- SkyLabs, a South Korean digital healthcare company, seeks FDA approval for U.S. market entry, while the FDA considers HLB Group's cancer drug.
- FDA and Pfizer are seeking regulatory approval for their products.
Coverage
Newest first; wire copies grouped- Unknown outlet
- Unknown outlet